pharma&’s Rubraca recommended by NICE

Privately-held Austria firm pharmaand GmbH (pharma&) today announced that the National Institute of Health and Care Excellence (NICE) has issued a positive recommendation for its Rubraca (rucaparib).

The UK health technology assessor issued Final Draft Guidance recommending the use of Rubraca in England, Wales and Northern Ireland as an option for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.

This is after complete or partial response to first-line platinum-based chemotherapy in adults, only if: it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or it is BRCA mutation negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option because NHS England’s BEV3 and BEV10 commissioning approval criteria for having it are not met, or it is contraindicated or not tolerated.